Clario, a leading provider of technologies and endpoint data solutions for clinical trials announced the enhancement of its digital capture of patient mobility data through the Mobilise-D consortium partnership. This collaboration integrates the recently validated Mobilise-D Digital Mobility Outcomes (DMOs) with Clario’s Opal® wearable sensor system, allowing clinicians to measure the way patients move in their daily life versus a single timepoint when they visit a clinic. DMOs deliver multiple advantages over conventional clinical scales when capturing information about human movement — they are more objective, reliable, accurate, and sensitive.
As a member of the Mobilise-D consortium, Clario provided essential technology and expertise for the e-clinical outcome assessments (eCOA) data capture, during both the technical and clinical validation studies that developed the algorithms. Leveraging this experience, Clario offers advanced solutions that integrate the validated Mobilise-D algorithms with its wearable sensors to assess mobility performance and deliver DMOs.
“It has been a privilege to contribute to the Mobilise-D consortium and advance digital mobility data for use in clinical trials,” said Kristen Sowalsky, Ph.D., D.C., VP, Product Management and Scientific Affairs, Precision Motion at Clario. “These developments are integral for demonstrating real-world patient outcomes, particularly in neuroscience where mobility insights outside of clinical settings are essential to assess treatment efficacy and quality-of-life.”
Clario is implementing these algorithms in a study with multiple sclerosis (MS) patients to establish the technical equivalence of its Precision Motion wearable device, Opal®️. In addition, Clario can provide the mobility performance data from wearable sensors along with e-clinical outcome assessments (eCOA), enhancing clinical outcomes. This, alongside Clario’s offerings in medical imaging, cardiac, and respiratory endpoints, meets a broad scope of clinical trial solutions addressing diverse needs.
Lynn Rochester, Ph.D., Professor of Human Movement Science at the Translational and Clinical Research Institute, Newcastle University in the United Kingdom co-led the Mobilise-D consortium. On the Clario partnership, Dr. Rochester said, “Working with Clario has been instrumental in our clinical studies to validate our DMO algorithms and ensuring their quality in clinical settings. Their expertise in data capture and analysis will contribute significantly to the success of our work, and we are excited about the future applications of this technology.”
